Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients
Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases, has selected AWS as its preferred cloud provider. Innovating on AWS and with the help of AWS experts and partners in healthcare and life sciences, Gilead provides its data scientists with the latest advances in machine learning and analytics. These capabilities fuel data-driven decision making across the organization—from biomarker discovery through manufacturing and clinical trial recruitment—and deliver insights that can help Gilead refine its drug pipeline. The company also relies on AWS to host all workloads for its enterprise resource planning (ERP) transformation project to implement SAP S/4HANA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005047/en/
“With AWS as our preferred cloud provider, our researchers can use AWS’s portfolio of services to gain the insights, agility, and security needed to deliver new medicines at speed, and treat the individual according to their unique needs, not just the disease,” said Marc Berson, Senior Vice President and Chief Information Officer at Gilead. “AWS’s performance, infrastructure, and scale are the foundations on which we will complete our ERP transformation and become a more efficient, agile, secure, and data-driven business in the cloud.”
Gilead is reimagining its bioinformatics compute infrastructure in the world’s leading cloud. The use of AWS’s compute, machine learning, and database capabilities will support the analysis and integration of diverse genomics, imaging, and experimental datasets to support breakthroughs in how Gilead diagnoses and treats diseases. For instance, by securely analyzing deidentified patient genomic data at scale on AWS to reveal patterns, Gilead can uncover insights on how people living with cancer respond to existing therapeutic options, potentially accelerating the discovery of new treatments.
Additionally, in its IT organization Gilead uses AWS to host all workloads for its ERP transformation project to implement SAP S/4HANA. These systems support business-critical processes in areas such as supply chain, finance, operations, and commercial sales across all therapeutic areas and business units. Running these processes on AWS provides the foundation for Gilead’s implementation of SAP S/4HANA. It also helps the company shorten hardware refresh cycles, increase testing and deployment agility, and gain visibility to improve business planning.
This is Gilead’s first implementation of production-scale ERP systems in the cloud, and AWS provides the company’s IT transformation team with scalable, secure, and high-performing infrastructure. Working alongside AWS, Gilead will integrate its SAP environments with a wide range of advanced AWS technologies in areas such as analytics and machine learning, uncovering business value and driving innovation. Moving forward, with AWS as the foundation of its new cloud-based SAP environment, the company will use a variety of Amazon Elastic Compute Cloud (Amazon EC2) instance types, including X1 and X1e instances built for high-performance databases, in-memory databases, and other memory-intensive enterprise applications, to run ERP workloads more efficiently.
In addition, Gilead has moved more than 50% of its data center footprint to AWS over the past 12 months through an accelerated cloud migration program with AWS Professional Services. The company also plans to migrate hundreds of applications to AWS, which include critical applications that support industry good practices (GxP) guidelines and regulations in areas like drug manufacturing, storage, and distribution. As a result, Gilead is accelerating its plans to upgrade its IT operations with AWS, while avoiding upfront costs to refresh hardware and the sustained costs of running an “always on,” on-premises IT landscape provisioned for peak use. As an additional element of the migration, the company is building an automated disaster recovery landscape in AWS. Doing so allows Gilead IT to optimize and scale its disaster recovery processes in the cloud to enhance resiliency.
With the help of AWS Professional Services and AWS experts in healthcare and life sciences, Gilead research and development teams are looking at ways to innovate in the cloud. They are taking an agile product development approach that uses microservices to optimize and automate operational processes throughout the company, and constructing new data architectures to uncover new insights more easily. Through the collaboration, Gilead aims to transform priority areas like clinical program and study design, patient experience, and centralized statistical adaptive monitoring, which helps Gilead quickly identify and address potential issues related to the management of clinical trials.
Gilead was also one of the first users of AWS for Health, an offering of curated AWS services and AWS Partner Network (APN) solutions now used by thousands of healthcare and life sciences customers globally. AWS for Health provides proven and easily accessible capabilities that help organizations increase the pace of innovation, unlock the potential of health data, and develop more personalized approaches to therapeutic development and care across 16 critical solution areas in healthcare, genomics, and biopharma.
“Gilead uses the proven performance of the world’s leading cloud to innovate, scale, and deliver powerful therapies for diseases like HIV and cancer, as well as advance standards for precision medicine. By streamlining their IT operations with AWS and taking advantage of our AWS for Health offerings, Gilead has the ability to continuously refine its approach to clinical trials, drug development, manufacturing, and distribution,” said Matt Garman, Senior Vice President of Sales and Marketing at Amazon Web Services, Inc. “AWS provides the security and privacy that healthcare and life sciences companies need, as well as the expertise and breadth and depth of services they can rely on to build transformative healthcare solutions that enhance health and wellbeing.”
About Amazon Web Services
For over 15 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud offering. AWS has been continually expanding its services to support virtually any cloud workload, and it now has more than 200 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 81 Availability Zones within 25 geographic regions, with announced plans for 27 more Availability Zones and nine more AWS Regions in Australia, Canada, India, Indonesia, Israel, New Zealand, Spain, Switzerland, and the United Arab Emirates. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.
For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed eleven HIV medications, including the first single tablet regimen to treat HIV and the first once-daily oral antiretroviral tablet for pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection. These advances in medical research have helped to transform HIV into a preventable, chronic condition for millions of people. Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships and collaborations, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere.
Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citi to Transform EMEA Headquarters in Major London Refurbishment26.1.2022 08:30:00 EET | Press release
Citi today announced its intent to transform its London headquarters, home to its UK and EMEA (Europe, Middle East and Africa) operations. The refurbishment of the iconic Citi Tower in Canary Wharf will create a stunning workplace for the future, incorporating the latest technology and the highest standards of environmental design. With flexible work and collaboration spaces, alongside well-being zones for employees, the transformation of Citi Tower represents Citi’s enduring commitment to its people, to London, and to delivering excellence for its clients around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125006049/en/ Conceptual image Citi Tower Interior (Graphic: Business Wire) “Our aim is to create an environmentally sustainable, innovative and exciting place to work, incorporating modern design, state-of-the-art technology, and best practices in employee and client spaces,” said David Livingstone, Citi’
Vending Machines International Secures SGD 135 Million Capital Commitment From Global Emerging Markets (GEM) as Company Seeks to Go Public26.1.2022 07:02:00 EET | Press release
Vending Machines International (VMI), today announced a SGD 135 Million capital commitment from GEM Global Yield LLC SCS ("GGY"), the Luxembourg-based private alternative investment vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125006251/en/ (Photo: Business Wire) Under the agreement, GGY will provide VMI with a Share Subscription Facility of up to SGD 135 million for a 36-month period following a public listing of VMI’s common stock. VMI will control the timing and maximum amount of drawdowns under this facility and has no minimum drawdown obligation. “VMI is very pleased to be selected by the GEM Group to receive this investment. It is a credit to the GEM management that they very quickly grasped that the world is moving to remove single use plastics from the supply chain. VMI is extremely well placed to take advantage of this transition. With GEM’s funds to strengthen the VMI balance sheet VMI will be able to
Private Messaging App Launches on Quantum Resistant, Decentralized xx network25.1.2022 18:30:00 EET | Press release
The world’s first quantum-resistant messaging app, xx messenger , launched on the xx network today. xx messenger allows users to communicate in real time through hundreds of decentralized nodes operating worldwide. The app is available for download on IOS and Android, features group chat as well as photo and audio sharing, and designed for easy use and switching to from legacy messaging apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005773/en/ David Chaum (Photo: Business Wire) Unlike existing messaging apps, xx messenger uses quantum-resistant cryptography to protect message content from decoding and cMix software to obfuscate or shred metadata—information about who sends, when they send, where they send from, and who receives. Randomly selected teams of xx nodes encrypt anonymity sets of 1,000 messages, which are then repeatedly shuffled and have also been encrypted using quantum-resistant cryptography. Informa
MDSLink Makes MaGiC™25.1.2022 18:00:00 EET | Press release
In response to the fiber buildout worldwide, and the continuous demand for reliable bandwidth, MDSLink, Inc. is now offering MaGiC™, a very high-performance, networking module that uses the existing coax. MaGiC is a cost-effective, easy-to-install module that extends the fiber footprint found in MDUs, single-family homes, hotels/resorts and offices or any building with existing coax. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005534/en/ MaGiC Small Form Factor Pluggable (Photo: Business Wire) MaGiC-SFP 2.5™ (Multi-Gigabit Coax Small Form-factor Pluggable) provides up to 2.5 Gbps—symmetrical—actual data rates when plugged into an Ethernet network (SFP/SFP+ port). Applications: - Last 100-meter distribution using existing, in-building coax. - Wireless AP backhaul in-premise. Supplements in-home Wi-Fi® mesh networks using fail safe, wireline backhaul between devices. Using WAPs with SFP-ports, operators can backhaul t
Kroll Unifies Brand to Reflect Strategic Growth and Vision25.1.2022 18:00:00 EET | Press release
Kroll, the leading provider of data, technology and insights related to risk, governance and growth, announces today the completion of its transition to a unified brand. Through its combined capabilities, Kroll is uniquely positioned to help clients stay ahead of complex business demands and opportunities across dynamic regulatory, economic and risk environments. “Our brand unification is a necessary evolution to deliver superior client service and meet and anticipate our clients’ increasingly complex and interconnected needs,” said Jacob Silverman, Chief Executive Officer of Kroll, “This marks the beginning of a new chapter for Kroll that reflects our market leadership across borders and disciplines, and embraces our proprietary data, technology and insights to create value and impact for our clients and communities.” Last year, the Company announced plans to unify its business following significant organic growth and strategic acquisitions. Kroll’s full suite of solutions now span se
Dr. Philip Krause to Provide Strategic Advice to Adjuvance25.1.2022 17:35:00 EET | Press release
Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced that Philip Krause, MD, will take on a strategic consulting role with the organization as it advances its vaccine development portfolio. Dr. Krause recently served as the Deputy Director, Office of Vaccines Research and Review of the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research. “The deep scientific, regulatory and vaccine development experience that Phil brings to Adjuvance will be instrumental in efficiently developing our shingles vaccine candidate and our pipeline anchored on the next-generation saponin adjuvant TQL-1055,” noted Dr. Tyler Martin, Adjuvance CEO, President and Chairman. “I am thrilled to enhance the company’s expertise with such a well-respected scientist.” Dr. Krause previously had a 30-year career in the FDA where he made majo
Andersen Global Adds Member Firms in Croatia25.1.2022 17:30:00 EET | Press release
Andersen Global continues to cultivate a strong European presence as Croatian tax and advisory firm Andersen BD d.o.o. (formerly BD Savjetovanje d.o.o.) becomes the organization’s newest member firm to adopt the Andersen brand. Andersen Global also welcomes member firm KALLAY & PARTNERS, a Zagreb-based law firm and collaborating firm since 2019. Together, the member firms will provide complementary tax and legal solutions, demonstrating the unified and seamless approach of the global organization. “As tax and legal legislation globally becomes more complex, we aim to continue providing best-in-class service and help our clients navigate the various aspects of their business operations,” said Branka Topolovec new Managing Partner of Andersen in Croatia. “The adoption of the Andersen brand is a milestone for our firm’s growth and development and gives us a competitive advantage in the market by allowing us to provide our clients with a full suite of capabilities in Croatia as well as glo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom